Belgium· BE-AMP-SAM664030-00
Lazcluze 240 mg
A lazertinib product containing lazertinib mesilate monohydrate, registered in Belgium by Janssen-Cilag International. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Lazertinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EB09 (lazertinib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Lazertinib · ATC L01EB09
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lazertinib costs, country by country.
Normalised to the WHO defined daily dose (0.24 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lazertinib · price per daily dose (0.24 g)
USD · FX 28 Sept 2026
- CH Switzerland$339.05
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Lazertinib Mesilate Monohydrate
- Manufacturer
- Janssen-Cilag International
- Country
- Belgium (BE)
- ATC code
- L01EB09
- ATC class
- Lazertinib
- Defined daily dose
- 0.24 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4925285
- be_apb7749393
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lazertinib in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLAZCLUZEJanssen-Cilag International N.V., Beerse
- NorwayLazcluzeJanssen-Cilag International N.V.
- FinlandLazcluzeJanssen Cilag International
- IrelandLazcluze 240 mg film-coated tabletsJanssen-Cilag International NV
- IcelandLazcluzeJanssen-Cilag International NV*
- NetherlandsLazcluze 240 mg filmomhulde tablettenJanssen-Cilag International NV
- PolandLazcluzeJanssen-Cilag International N.V.
- SwedenLazcluze 240 mg Filmdragerad tablettJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lazcluze
- Liechtenstein · Lazcluze
- Norway · Lazcluze
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e3ca8f30-ec47-4141-9633-0adc1205ce34 GET /v1/drugs/e3ca8f30-ec47-4141-9633-0adc1205ce34?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Lazcluze 240 mg",
"name_fr": "Lazcluze 240 mg",
"name_nl": "Lazcluze 240 mg",
"amp_code": "SAM664030-00",
"strengths": [
"240.0000",
"240.0000"
],
"pack_count": 3,
"substances": [
"Lazertinib Mesilate Monohydrate",
"Lazertinib",
"Mannitol"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Lazertinib",
"authorisation_numbers": [
"EU/1/24/1886/005",
"EU/1/24/1886/004",
"EU/1/24/1886/006"
]
}See everything about lazertinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.